CA2462512A1 - Use of collagenase to facilitate guide wire crossing in total arterial occlusions - Google Patents
Use of collagenase to facilitate guide wire crossing in total arterial occlusions Download PDFInfo
- Publication number
- CA2462512A1 CA2462512A1 CA002462512A CA2462512A CA2462512A1 CA 2462512 A1 CA2462512 A1 CA 2462512A1 CA 002462512 A CA002462512 A CA 002462512A CA 2462512 A CA2462512 A CA 2462512A CA 2462512 A1 CA2462512 A1 CA 2462512A1
- Authority
- CA
- Canada
- Prior art keywords
- proteolytic enzyme
- containing formulation
- occlusion
- enzyme containing
- waiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
Abstract
The use of a collagenase containing formulation for degrading collagen within an occlusive atherosclerotic plaque in a chronically occluded animal tube or cavity. A medical-related apparatus is provided comprising a medical-related device having provided thereto a therapeutic amount of a collagen degrading composition comprising a proteiolytic enzyme containing formulation. A
method of is provided for treating chronically occluded animal tubes and cavities by administering a therapeutic effective amount of a proteolytic enzyme-containing formulation adjacent to an occluding atherosclerotic plaque, waiting for a pre-angioplasty waiting period, followed by crossing the plaque with an angioplasty guide wire.
method of is provided for treating chronically occluded animal tubes and cavities by administering a therapeutic effective amount of a proteolytic enzyme-containing formulation adjacent to an occluding atherosclerotic plaque, waiting for a pre-angioplasty waiting period, followed by crossing the plaque with an angioplasty guide wire.
Claims (32)
1. A method of developing a chronic arterial occlusions in-vivo animal model comprising the steps of:
isolating a segment of an animal artery;
stopping blood flow with occlusive ligatures in the isolated arterial segment of an animal artery;
injecting topical thrombin into the isolated arterial segment to form an acute thrombotic occlusion;
waiting while the acute thrombotic occlusion is converted into a chronic fibrotic occlusion.
isolating a segment of an animal artery;
stopping blood flow with occlusive ligatures in the isolated arterial segment of an animal artery;
injecting topical thrombin into the isolated arterial segment to form an acute thrombotic occlusion;
waiting while the acute thrombotic occlusion is converted into a chronic fibrotic occlusion.
2. The method of claim 1 wherein the steps of isolating an arterial segment further comprises the steps of:
anaesthetizing an animal;
making an incision to access the artery; and, placing ligatures at least about 5 mm apart to isolate a segment of artery.
anaesthetizing an animal;
making an incision to access the artery; and, placing ligatures at least about 5 mm apart to isolate a segment of artery.
3. The method of claim 1 wherein the step of injecting the topical thrombin to form an acute thrombotic occlusion comprises the steps of:
injecting a bovine thrombin solution into the arterial segment using a needle;
waiting for a first waiting period;
loosening the ligature to determine if an occlusion has formed;
determining whether anterograde blood flow is still present;
if anterograde blood flow is still present, injecting additional bovine thrombin solution into the arterial segment;
repeating until an acute thrombotic occlusion is formed; and removing the ligatures.
injecting a bovine thrombin solution into the arterial segment using a needle;
waiting for a first waiting period;
loosening the ligature to determine if an occlusion has formed;
determining whether anterograde blood flow is still present;
if anterograde blood flow is still present, injecting additional bovine thrombin solution into the arterial segment;
repeating until an acute thrombotic occlusion is formed; and removing the ligatures.
4. The method of claim 3 wherein the first waiting period is at least 20 minutes.
5. The method of claim 1 wherein the duration of the step of waiting while the acute thrombotic occlusion is converted into a chronic fibrotic occlusion is 10 to 25 weeks.
6. The method of claim 1 wherein the animal is selected from the group consisting of rabbits, pigs, dogs, sheep, rats and non-human primates.
7. The method of claim 1 wherein the artery is selected from the group consisting of femoral, iliac, carotid, and coronary arteries.
8. An in-vivo animal model of chronic arterial occlusions formed by means of stopping blood flow with occlusive ligatures in an isolated arterial segment of an animal artery; injecting topical thrombin into the arterial segment to form an acute thrombotic occlusion; and, waiting while the acute thrombotic occlusion is converted into a chronic fibrotic occlusion.
9. A method of treating chronically occluded animal tubes and cavities comprising the steps of:
administering a therapeutic effective amount of a proteolytic enzyme containing formulation adjacent an occluding atherosclerotic plaque;
waiting for a pre-angioplasty waiting period; and, crossing the plaque with an angioplasty guide wire.
administering a therapeutic effective amount of a proteolytic enzyme containing formulation adjacent an occluding atherosclerotic plaque;
waiting for a pre-angioplasty waiting period; and, crossing the plaque with an angioplasty guide wire.
10. The method of claim 9 wherein the duration of the pre-angioplasty waiting period is between about 1 hour and about 108 hours.
11. The method of claim 10 wherein the duration of the pre-angioplasty waiting period is between about 12 hours and about 86 hours.
12. The method of claim 11 wherein the duration of the pre-angioplasty waiting period is about 72 hours.
13. The method of claim 9 wherein the step of administering a therapeutic effective amount of a proteolytic enzyme containing formulation comprises the steps of:
advancing an over-the-wire angioplasty balloon catheter on a guide wire into the occluded tube or cavity using fluoroscopic guidance;
inflating the balloon at low pressure;
removing the guide wire;
infusing a proteolytic enzyme formulation into the tube or cavity lumen;
waiting for a formulation exposure waiting period; and, removing the angioplasty equipment.
advancing an over-the-wire angioplasty balloon catheter on a guide wire into the occluded tube or cavity using fluoroscopic guidance;
inflating the balloon at low pressure;
removing the guide wire;
infusing a proteolytic enzyme formulation into the tube or cavity lumen;
waiting for a formulation exposure waiting period; and, removing the angioplasty equipment.
14. The method of claim 13 wherein the proteolytic enzyme containing formulation is infused into the tube or cavity lumen proximal to the occlusion.
15. The method of claim 13 wherein the proteolytic enzyme containing formulation is directly into the proximal part of the occlusion.
16. The method of claim 13 wherein the infusion of the proteolytic enzyme containing formulation is through the wire port of an angioplasty catheter.
17. The method of claim 13 wherein the infusion of the proteolytic enzyme containing formulation is through an infusion needle.
18. The method of claim 13 wherein the infusion of the proteolytic enzyme containing formulation is through a catheter.
19. The method of claim 13 wherein the balloon is inflated to a pressure in the range of about 1-5 atmospheres.
20. The method of claim 20 wherein the balloon is inflated to a pressure of about 4 atmospheres.
21.The method of claim 13 wherein the proteolytic enzyme containing formulation is infused under low pressure.
22. The method of claim 21 wherein the proteolytic enzyme containing formulation is infused under a pressure in the range of about 0.5 atmospheres to 3.5 atmospheres.
23. The method of claim 22 wherein the proteolytic enzyme containing formulation is infused under a pressure in the range of about 1 to 2 atmospheres.
24. The method of claim 13 wherein the formulation exposure waiting period is at least about 10 minutes.
25. The method of claim 24 wherein the formulation exposure waiting period is between about 20 minutes and about 100 minutes.
26. The method of claim 25 wherein the formulation exposure waiting period is between about 50 minutes and about 80 minutes.
27. The method of claim 26 wherein the formulation exposure waiting period is between about 60 minutes.
28. The method claim 9 wherein the proteolytic enzyme containing formulation comprises a proteolytic enzyme selected from the group consisting of matrix metalloproteinases, serine elastases, trypsin, neutral protease, chymotrypsin, aspartase, cysteinase and clostripain, and human purified matrix degrading enzymes.
29. The method claim 28 wherein the proteolytic enzyme containing formulation comprises a matrix metalloproteinases selected from the group consisting of collagenase, type 1A collagenase, gelatinases, and stromelysin, and human purified matrix degrading enzymes.
30. The method claim 28 wherein the proteolytic enzyme containing formulation comprises collagenase containing formulation.
31. The method claim 9 wherein the effective therapeutic amount of proteolytic enzyme containing formulation comprises 50 - 2000 µg of type IA Collagenase.
32. A method of developing a chronic occlusions in-vivo animal model comprising the steps of:
isolating a segment of an animal tube;
stopping fluid flow through the tube with occlusive ligatures in the isolated segment of an animal tube;
injecting topical sclerosing agent into the isolated segment to form an acute occlusion;
waiting while the acute occlusion is converted into a chronic fibrotic occlusion.
isolating a segment of an animal tube;
stopping fluid flow through the tube with occlusive ligatures in the isolated segment of an animal tube;
injecting topical sclerosing agent into the isolated segment to form an acute occlusion;
waiting while the acute occlusion is converted into a chronic fibrotic occlusion.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32553901P | 2001-10-01 | 2001-10-01 | |
| US60/325,539 | 2001-10-01 | ||
| PCT/CA2002/001476 WO2003028756A2 (en) | 2001-10-01 | 2002-10-01 | An in vivo animal model of chronic arterial occlusion and use of collagenase to facilitate guide wire crossing in chronic arterial occlusions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2462512A1 true CA2462512A1 (en) | 2003-04-10 |
| CA2462512C CA2462512C (en) | 2013-11-05 |
Family
ID=23268311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2462512A Expired - Lifetime CA2462512C (en) | 2001-10-01 | 2002-10-01 | Use of collagenase to facilitate guide wire crossing in total arterial occlusions |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20050053548A1 (en) |
| EP (1) | EP1438065B1 (en) |
| JP (1) | JP2005503820A (en) |
| CN (1) | CN1327893C (en) |
| AU (1) | AU2002328729C1 (en) |
| CA (1) | CA2462512C (en) |
| DK (1) | DK1438065T3 (en) |
| ES (1) | ES2396964T3 (en) |
| HK (1) | HK1076037A1 (en) |
| IL (2) | IL161137A0 (en) |
| PT (1) | PT1438065E (en) |
| SI (1) | SI1438065T1 (en) |
| WO (1) | WO2003028756A2 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003525048A (en) * | 2000-03-02 | 2003-08-26 | インサイト・ゲノミックス・インコーポレイテッド | Lipid metabolizing enzymes |
| US6569129B1 (en) * | 2000-09-13 | 2003-05-27 | Mayo Foundation For Medical Education And Research | Biological revascularization |
| SI1438065T1 (en) * | 2001-10-01 | 2013-03-29 | Martizyme Pharma Corporation | Use of collagenase to facilitate guide wire crossing in chronic arterial occlusions |
| WO2005097177A1 (en) * | 2004-04-08 | 2005-10-20 | Strauss Bradley H | Use of collagenase to facilitate guide wire crossing in total arterial occlusions |
| EP1827484B1 (en) * | 2004-12-02 | 2015-06-17 | Bradley H. Strauss | Augmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions |
| JP2007181413A (en) * | 2006-01-05 | 2007-07-19 | Fujifilm Corp | Method for creating vascular wall-damaged model animal |
| US20070184083A1 (en) * | 2006-02-07 | 2007-08-09 | Medtronic Vascular, Inc. | Drug-Eluting Device for Treatment of Chronic Total Occlusions |
| US8541370B2 (en) | 2007-02-26 | 2013-09-24 | Proyecto De Biomedicina Cima, S.L. | Use of matrix metalloproteinase-10 (MMP-10) for thrombolytic treatments |
| ES2335167B1 (en) * | 2007-02-26 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | USE OF METALOPROTEINASE MATRIX-10 (MMP10) FOR THROMBOLITIC TREATMENTS. |
| US10071143B1 (en) | 2007-05-03 | 2018-09-11 | The Research Foundation For The State University Of New York | Methods for non-surgical treatment of carpal tunnel syndrome |
| US8016799B2 (en) * | 2008-04-22 | 2011-09-13 | Medtronic Vascular, Inc. | Catheter having a detachable tip |
| WO2011130537A2 (en) * | 2010-04-14 | 2011-10-20 | Northwestern University | Pharmaceutical compositions and methods for digesting atherosclerotic plaques |
| US20120259314A1 (en) * | 2011-04-11 | 2012-10-11 | Medtronic Vascular, Inc. | Apparatus and Methods for Recanalization of a Chronic Total Occlusion |
| CN103157099B (en) * | 2011-12-19 | 2015-03-18 | 吴宗贵 | Mixed enzyme digestive juice for fast digestion of vascular adventitia and preparation method thereof |
| US9636385B2 (en) | 2012-10-24 | 2017-05-02 | The Research Foundation For The State University Of New York | Use of collagenase to treat glaucoma |
| WO2014134532A1 (en) * | 2013-02-28 | 2014-09-04 | Ventrix, Inc. | Methods and compositions for tissue therapy and analysis |
| CN103340663B (en) * | 2013-06-17 | 2016-05-04 | 李宝童 | Capsule formula coronary artery [Dan and chronic myocardial ischemia animal model manufacture method |
| EP3554626A4 (en) * | 2016-12-15 | 2020-06-03 | Luseed Vascular Ltd. | Methods and devices for treating vascular related disorders |
| EA202190494A1 (en) * | 2018-06-28 | 2021-12-09 | Маризим Байотек | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THROMBOSIS TREATMENT AND DELIVERY USING MEDICAL DEVICES |
| US20220265291A9 (en) * | 2018-06-28 | 2022-08-25 | Marizyme, Inc. | Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices |
| CN115245143A (en) * | 2022-07-06 | 2022-10-28 | 上海市中西医结合医院 | Construction method of artery occlusive disease animal model |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4636195A (en) * | 1982-04-02 | 1987-01-13 | Harvey Wolinsky | Method and apparatus for removing arterial constriction |
| US5955584A (en) * | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| US6025477A (en) | 1986-03-31 | 2000-02-15 | Calenoff; Emanuel | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| US5811248A (en) | 1986-03-31 | 1998-09-22 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| US5163421A (en) * | 1988-01-22 | 1992-11-17 | Angiosonics, Inc. | In vivo ultrasonic system with angioplasty and ultrasonic contrast imaging |
| US5024829A (en) * | 1988-11-21 | 1991-06-18 | Centocor, Inc. | Method of imaging coronary thrombi |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| JPH05501855A (en) * | 1989-05-17 | 1993-04-08 | リサーチ、コーポレーション、テクノロジーズ、インコーポレーテッド | Methods and compositions for treating thrombosis in mammals |
| US5422261A (en) * | 1993-04-16 | 1995-06-06 | Baxter International Inc. | Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells |
| US5613949A (en) * | 1994-04-01 | 1997-03-25 | Advanced Cardiovascular Systems, Inc. | Double balloon catheter assembly |
| US5540637A (en) | 1995-01-25 | 1996-07-30 | Ccs, Llc | Stationary exercise apparatus having a preferred foot platform orientation |
| US6020181A (en) | 1995-05-17 | 2000-02-01 | New York Blood, Inc. | Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase |
| US6306166B1 (en) * | 1997-08-13 | 2001-10-23 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
| EP0920882A3 (en) | 1997-12-04 | 2000-01-05 | Schneider Inc. | Balloon dilatation-drug delivery catheter and stent deployment-drug delivery catheter in rapid exchange configuration |
| EP1060747A3 (en) * | 1999-06-16 | 2001-12-05 | New York Blood Center, Inc. | Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase |
| US6569129B1 (en) | 2000-09-13 | 2003-05-27 | Mayo Foundation For Medical Education And Research | Biological revascularization |
| US6623452B2 (en) * | 2000-12-19 | 2003-09-23 | Scimed Life Systems, Inc. | Drug delivery catheter having a highly compliant balloon with infusion holes |
| US6780849B2 (en) * | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
| US6808518B2 (en) | 2001-09-28 | 2004-10-26 | Ethicon, Inc. | Methods and devices for treating diseased blood vessels |
| SI1438065T1 (en) * | 2001-10-01 | 2013-03-29 | Martizyme Pharma Corporation | Use of collagenase to facilitate guide wire crossing in chronic arterial occlusions |
-
2002
- 2002-10-01 SI SI200231019T patent/SI1438065T1/en unknown
- 2002-10-01 CN CNB028241029A patent/CN1327893C/en not_active Expired - Fee Related
- 2002-10-01 WO PCT/CA2002/001476 patent/WO2003028756A2/en active Application Filing
- 2002-10-01 US US10/491,424 patent/US20050053548A1/en not_active Abandoned
- 2002-10-01 AU AU2002328729A patent/AU2002328729C1/en not_active Ceased
- 2002-10-01 DK DK02764443.4T patent/DK1438065T3/en active
- 2002-10-01 PT PT2764443T patent/PT1438065E/en unknown
- 2002-10-01 EP EP02764443A patent/EP1438065B1/en not_active Expired - Lifetime
- 2002-10-01 ES ES02764443T patent/ES2396964T3/en not_active Expired - Lifetime
- 2002-10-01 IL IL16113702A patent/IL161137A0/en unknown
- 2002-10-01 JP JP2003532086A patent/JP2005503820A/en active Pending
- 2002-10-01 CA CA2462512A patent/CA2462512C/en not_active Expired - Lifetime
-
2004
- 2004-03-29 IL IL161137A patent/IL161137A/en active IP Right Grant
-
2005
- 2005-09-16 HK HK05108158A patent/HK1076037A1/en not_active IP Right Cessation
-
2006
- 2006-09-22 US US11/534,351 patent/US7425326B2/en not_active Expired - Lifetime
-
2008
- 2008-09-16 US US12/211,574 patent/US8021660B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050053548A1 (en) | 2005-03-10 |
| WO2003028756A3 (en) | 2003-08-28 |
| WO2003028756A2 (en) | 2003-04-10 |
| ES2396964T3 (en) | 2013-03-01 |
| IL161137A (en) | 2014-08-31 |
| AU2002328729A2 (en) | 2003-04-14 |
| SI1438065T1 (en) | 2013-03-29 |
| HK1076037A1 (en) | 2006-01-06 |
| CN1327893C (en) | 2007-07-25 |
| US7425326B2 (en) | 2008-09-16 |
| US20090074744A1 (en) | 2009-03-19 |
| AU2002328729C1 (en) | 2009-11-26 |
| IL161137A0 (en) | 2004-08-31 |
| JP2005503820A (en) | 2005-02-10 |
| EP1438065B1 (en) | 2012-11-21 |
| DK1438065T3 (en) | 2013-02-11 |
| US20070014783A1 (en) | 2007-01-18 |
| EP1438065A2 (en) | 2004-07-21 |
| CA2462512C (en) | 2013-11-05 |
| PT1438065E (en) | 2013-01-24 |
| CN1599621A (en) | 2005-03-23 |
| AU2002328729B2 (en) | 2009-07-16 |
| US8021660B2 (en) | 2011-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2462512A1 (en) | Use of collagenase to facilitate guide wire crossing in total arterial occlusions | |
| US7316911B2 (en) | Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases | |
| WO2001036609A8 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| AU6936600A (en) | Catheter devices and methods for their use in the treatment of calcified vascular occlusions | |
| Paulsen et al. | Use of tissue plasminogen activator for reopening of clotted dialysis catheters | |
| AU2002328729A1 (en) | Use of collagenase to facilitate guide wire crossing in total arterial occlusions | |
| ES2284528T3 (en) | USE OF ELASTASE TO OPEN ARTERIES AND OBSTRUCTED VEINS. | |
| ES2242655T3 (en) | USE OF FIBRINOLITIC METALOPROTEINASES FOR THE THERAPEUTIC TREATMENT OF BLOOD COAGULES. | |
| Saito et al. | Pulse‐spray thrombolysis in acutely obstructed coronary artery in critical situations | |
| King et al. | Fibrinolysin therapy for thrombosis of priapism | |
| Bonde et al. | Salvage of free flaps after venous thrombosis: case report | |
| Hartley et al. | The use of urokinase in Scribner shunts | |
| Tawa Jr et al. | Angioaccess in the renal failure patient | |
| Jorgensen et al. | Intra-arterial thrombin activity produced by percutaneous transluminal angioplasty eliminated by segmentally enclosed thrombolysis | |
| Blanshard et al. | Fibrinolytic therapy for infra-inguinal synthetic graft occlusions | |
| JP2004516273A (en) | Use of activated coagulation factor VII to treat thrombolytic therapy-induced major bleeding | |
| CN112638289A (en) | Pharmaceutical compositions and methods for treating thrombosis and medical device delivery | |
| Sciolaro et al. | Thrombectomy and isolated limb perfusion with urokinase in the treatment of phlegmasia cerulea dolens | |
| Molinari et al. | The activity of rtcu-PA generated from rscu-PA during lysis of plasma clots in vitro is not affected by the heparin-dependent u-PA inhibitors | |
| UA135727U (en) | METHOD OF TREATMENT OF ACUTE PROXIMAL THROMBOSIS OF DEEP VEINS OF LOWER LIMBS | |
| JPWO2020006444A5 (en) | ||
| Schmutzler | Thrombolytic Therapy in the Elderly | |
| AU2006202029A1 (en) | Method for localized administration of fibrinolytic metalloproteinases | |
| Ackermann et al. | Balloon Occlusion of the Renal Artery and Its Clinical Application | |
| Zhou et al. | Mechanical Thrombectomy and Thrombolysis for Acute Deep Venous Thrombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20221003 |